Literature DB >> 19748551

Fractalkine/CX3CL1 enhances GABA synaptic activity at serotonin neurons in the rat dorsal raphe nucleus.

S Heinisch1, L G Kirby.   

Abstract

Serotonin (5-hydroxytryptamine; 5-HT) has an important role in mood regulation, and its dysfunction in the central nervous system (CNS) is associated with depression. Reports of mood and immune disorder co-morbidities indicate that immune-5-HT interactions may mediate depression present in immune compromised disease states including HIV/AIDS, multiple sclerosis, and Parkinson's disease. Chemokines, immune proteins that induce chemotaxis and cellular adhesion, and their G-protein coupled receptors distribute throughout the CNS, regulate neuronal patterning, and mediate neuropathology. The purpose of this study is to investigate the neuroanatomical and neurophysiological relationship between the chemokine fractalkine/CX3CL1 and its receptor CX3CR1 with 5-HT neurons in the rat midbrain raphe nuclei (RN). Immunohistochemistry was used to examine the colocalization of CX3CL1 or CX3CR1 with 5-HT in the RN, and whole-cell patch-clamp recordings in rat brain slices were used to determine the functional impact of CX3CL1 on 5-HT dorsal raphe nucleus (DRN) neurons. Greater than 70% of 5-HT neurons colocalize with CX3CL1 and CX3CR1 in the RN. CX3CL1 localizes as discrete puncta throughout the cytoplasm, whereas CX3CR1 concentrates to the perinuclear region of 5-HT neurons and exhibits microglial expression. CX3CL1 and CX3CR1 also colocalize with one another on individual RN cells. Electrophysiology studies indicate a CX3CL1-mediated enhancement of spontaneous inhibitory postsynaptic current (sIPSC) amplitude and dose-dependent increase of evoked IPSC (eIPSC) amplitude without affecting eIPSC paired-pulse ratio, a finding observed selectively in 5-HT neurons. CX3CL1's effect on eIPSC amplitude is blocked by pretreatment with an anti-CX3CL1 neutralizing antibody. Thus, CX3CL1 enhances postsynaptic GABA receptor number or sensitivity on 5-HT DRN neurons under conditions of both spontaneous and synaptically-evoked GABA release. CX3CL1 may indirectly inhibit 5-HT neurotransmission by increasing the sensitivity of 5-HT DRN neurons to GABA inputs. Therapies targeting CX3CL1 may treat serotonin related mood disorders, including depression experienced by patients with compromised immune systems.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19748551      PMCID: PMC2785445          DOI: 10.1016/j.neuroscience.2009.08.075

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  59 in total

1.  Increased number of synaptic GABA(A) receptors underlies potentiation at hippocampal inhibitory synapses.

Authors:  Z Nusser; N Hájos; P Somogyi; I Mody
Journal:  Nature       Date:  1998-09-10       Impact factor: 49.962

2.  A new class of membrane-bound chemokine with a CX3C motif.

Authors:  J F Bazan; K B Bacon; G Hardiman; W Wang; K Soo; D Rossi; D R Greaves; A Zlotnik; T J Schall
Journal:  Nature       Date:  1997-02-13       Impact factor: 49.962

3.  Recruitment of functional GABA(A) receptors to postsynaptic domains by insulin.

Authors:  Q Wan; Z G Xiong; H Y Man; C A Ackerley; J Braunton; W Y Lu; L E Becker; J F MacDonald; Y T Wang
Journal:  Nature       Date:  1997-08-14       Impact factor: 49.962

4.  GABA in the mammalian suprachiasmatic nucleus and its role in diurnal rhythmicity.

Authors:  S Wagner; M Castel; H Gainer; Y Yarom
Journal:  Nature       Date:  1997-06-05       Impact factor: 49.962

5.  Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion.

Authors:  T Imai; K Hieshima; C Haskell; M Baba; M Nagira; M Nishimura; M Kakizaki; S Takagi; H Nomiyama; T J Schall; O Yoshie
Journal:  Cell       Date:  1997-11-14       Impact factor: 41.582

6.  Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1.

Authors:  C Combadiere; K Salzwedel; E D Smith; H L Tiffany; E A Berger; P M Murphy
Journal:  J Biol Chem       Date:  1998-09-11       Impact factor: 5.157

7.  Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia.

Authors:  J K Harrison; Y Jiang; S Chen; Y Xia; D Maciejewski; R K McNamara; W J Streit; M N Salafranca; S Adhikari; D A Thompson; P Botti; K B Bacon; L Feng
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

8.  Increase of tryptophan hydroxylase enzyme protein by dexamethasone in adrenalectomized rat midbrain.

Authors:  E C Azmitia; B Liao; Y S Chen
Journal:  J Neurosci       Date:  1993-12       Impact factor: 6.167

9.  Corticotropin-releasing factor increases GABA synaptic activity and induces inward current in 5-hydroxytryptamine dorsal raphe neurons.

Authors:  Lynn G Kirby; Emily Freeman-Daniels; Julia C Lemos; John D Nunan; Christophe Lamy; Adaure Akanwa; Sheryl G Beck
Journal:  J Neurosci       Date:  2008-11-26       Impact factor: 6.167

10.  Localization of fractalkine and CX3CR1 mRNAs in rat brain: does fractalkine play a role in signaling from neuron to microglia?

Authors:  A Nishiyori; M Minami; Y Ohtani; S Takami; J Yamamoto; N Kawaguchi; T Kume; A Akaike; M Satoh
Journal:  FEBS Lett       Date:  1998-06-12       Impact factor: 4.124

View more
  22 in total

1.  Interactions between chemokine and mu-opioid receptors: anatomical findings and electrophysiological studies in the rat periaqueductal grey.

Authors:  Silke Heinisch; Jonathan Palma; Lynn G Kirby
Journal:  Brain Behav Immun       Date:  2010-10-23       Impact factor: 7.217

2.  Differential expression and HIV-1 regulation of μ-opioid receptor splice variants across human central nervous system cell types.

Authors:  Seth M Dever; Ruqiang Xu; Sylvia Fitting; Pamela E Knapp; Kurt F Hauser
Journal:  J Neurovirol       Date:  2012-04-20       Impact factor: 2.643

3.  CX3CR1 RNAi inhibits hypoxia-induced microglia activation via p38MAPK/PKC pathway.

Authors:  Yong Liu; Tianzhi Zhao; Zhao Yang; Qianning Li
Journal:  Int J Exp Pathol       Date:  2014-04       Impact factor: 1.925

4.  Chemokines gene expression in the prefrontal cortex of depressed suicide victims and normal control subjects.

Authors:  Ghanshyam N Pandey; Hooriyah S Rizavi; Runa Bhaumik; Hui Zhang
Journal:  Brain Behav Immun       Date:  2021-02-09       Impact factor: 7.217

Review 5.  Systematic Review of the Neurobiological Relevance of Chemokines to Psychiatric Disorders.

Authors:  Michael J Stuart; Gaurav Singhal; Bernhard T Baune
Journal:  Front Cell Neurosci       Date:  2015-09-10       Impact factor: 5.505

Review 6.  Neuron-glia crosstalk in health and disease: fractalkine and CX3CR1 take centre stage.

Authors:  Graham K Sheridan; Keith J Murphy
Journal:  Open Biol       Date:  2013-12-18       Impact factor: 6.411

Review 7.  Fractalkine regulation of microglial physiology and consequences on the brain and behavior.

Authors:  Rosa Chiara Paolicelli; Kanchan Bisht; Marie-Ève Tremblay
Journal:  Front Cell Neurosci       Date:  2014-05-13       Impact factor: 5.505

8.  Molecular and cellular neuroinflammatory status of mouse brain after systemic lipopolysaccharide challenge: importance of CCR2/CCL2 signaling.

Authors:  Julie Cazareth; Alice Guyon; Catherine Heurteaux; Joëlle Chabry; Agnès Petit-Paitel
Journal:  J Neuroinflammation       Date:  2014-07-28       Impact factor: 8.322

9.  Modulation of firing and synaptic transmission of serotonergic neurons by intrinsic G protein-coupled receptors and ion channels.

Authors:  Takashi Maejima; Olivia A Masseck; Melanie D Mark; Stefan Herlitze
Journal:  Front Integr Neurosci       Date:  2013-05-23

10.  CX3CL1 is up-regulated in the rat hippocampus during memory-associated synaptic plasticity.

Authors:  Graham K Sheridan; Anita Wdowicz; Mark Pickering; Orla Watters; Paul Halley; Niamh C O'Sullivan; Claire Mooney; David J O'Connell; John J O'Connor; Keith J Murphy
Journal:  Front Cell Neurosci       Date:  2014-08-12       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.